These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 37793423)

  • 1. Interval post-colonoscopy colorectal cancer following a negative colonoscopy in a fecal immunochemical test-based screening program.
    van de Schootbrugge-Vandermeer HJ; Kooyker AI; Wisse PHA; Nagtegaal ID; Geuzinge HA; Toes-Zoutendijk E; de Jonge L; Breekveldt ECH; van Vuuren AJ; van Kemenade FJ; Ramakers CRB; Dekker E; Lansdorp-Vogelaar I; Spaander MCW; van Leerdam ME
    Endoscopy; 2023 Dec; 55(12):1061-1069. PubMed ID: 37793423
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The multitarget fecal immunochemical test versus the fecal immunochemical test for programmatic colorectal cancer screening: a cross-sectional intervention study with paired design.
    Wisse PHA; de Klaver W; van Wifferen F; Meiqari L; Bierkens M; Greuter MJE; Carvalho B; van Leerdam ME; Spaander MCW; Dekker E; Coupé VMH; de Wit M; Meijer GA
    BMC Cancer; 2022 Dec; 22(1):1299. PubMed ID: 36503495
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interval cancers in a population-based screening program for colorectal cancer with gender-specific cut-off levels for fecal immunochemical test.
    Ribbing Wilén H; Saraste D; Blom J
    J Med Screen; 2022 Sep; 29(3):156-165. PubMed ID: 35257615
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multiple Negative Fecal Immunochemical Tests Reduce Risk of Advanced Neoplasia in a Colonoscopy Surveillance Program.
    Wassie MM; Young GP; Winter JM; Cock C; Bampton P; Rahman M; Heddle R; Fraser R; Meng R; Symonds EL
    Clin Gastroenterol Hepatol; 2023 Aug; 21(9):2389-2398.e2. PubMed ID: 36610499
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interval Colorectal Cancer Incidence Among Subjects Undergoing Multiple Rounds of Fecal Immunochemical Testing.
    van der Vlugt M; Grobbee EJ; Bossuyt PMM; Bos A; Bongers E; Spijker W; Kuipers EJ; Lansdorp-Vogelaar I; Spaander MCW; Dekker E
    Gastroenterology; 2017 Aug; 153(2):439-447.e2. PubMed ID: 28483499
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Factors associated with interval colorectal cancer after negative FIT: Results of two screening rounds in the Dutch FIT-based CRC screening program.
    Breekveldt ECH; Toes-Zoutendijk E; van de Schootbrugge-Vandermeer HJ; de Jonge L; Kooyker AI; Spaander MCW; van Vuuren AJ; van Kemenade FJ; Ramakers C; Dekker E; Nagtegaal ID; van Leerdam ME; Lansdorp-Vogelaar I
    Int J Cancer; 2023 Apr; 152(8):1536-1546. PubMed ID: 36444504
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Screening for Colorectal Cancer With Fecal Immunochemical Testing With and Without Postpolypectomy Surveillance Colonoscopy: A Cost-Effectiveness Analysis.
    Greuter MJE; de Klerk CM; Meijer GA; Dekker E; Coupé VMH
    Ann Intern Med; 2017 Oct; 167(8):544-554. PubMed ID: 28973514
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Features of Fecal Immunochemical Test-Negative Colorectal Lesions based on Colorectal Cancer Screening among Asymptomatic Participants in Their 50s.
    Suto S; Matsuzaka M; Sawaya M; Sakuraba H; Mikami T; Matsuda T; Fujii T; Saito Y; Hotta K; Ikematsu H; Hanabata N; Saito H; Yoshida S; Fukuda S
    Asian Pac J Cancer Prev; 2022 Jul; 23(7):2325-2332. PubMed ID: 35901338
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnostic Yield of One-Time Colonoscopy vs One-Time Flexible Sigmoidoscopy vs Multiple Rounds of Mailed Fecal Immunohistochemical Tests in Colorectal Cancer Screening.
    Grobbee EJ; van der Vlugt M; van Vuuren AJ; Stroobants AK; Mallant-Hent RC; Lansdorp-Vogelaar I; Bossuyt PMM; Kuipers EJ; Dekker E; Spaander MCW
    Clin Gastroenterol Hepatol; 2020 Mar; 18(3):667-675.e1. PubMed ID: 31419575
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Faecal immunochemical test after negative colonoscopy may reduce the risk of incident colorectal cancer in a population-based screening programme.
    Peng SM; Hsu WF; Wang YW; Lin LJ; Yen AM; Chen LS; Lee YC; Wu MS; Chen TH; Chiu HM
    Gut; 2021 Jul; 70(7):1318-1324. PubMed ID: 32989019
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Colonoscopy-Related Mortality in a Fecal Immunochemical Test-Based Colorectal Cancer Screening Program.
    Kooyker AI; Toes-Zoutendijk E; Opstal-van Winden AWJ; Buskermolen M; van Vuuren HJ; Kuipers EJ; van Kemenade FJ; Ramakers C; Dekker E; Nagtegaal ID; de Koning HJ; Spaander MCW; Lansdorp-Vogelaar I; van Leerdam ME
    Clin Gastroenterol Hepatol; 2021 Jul; 19(7):1418-1425. PubMed ID: 32777553
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Short Term Outcomes of Using Fecal Immunochemical Test for a Pilot Colorectal Cancer Screening Program. A Single Center Study on 3024 Consecutive Patients.
    Constantin A; Cazacu I; Ciocârlan M; Constantinescu C; Baltog G; Balahura C; Doraş I; Filip S; Filip G; Panazan I; Piţigoi D; Pirvu V; Turcu F; Copăescu C; Săftoiu A
    Chirurgia (Bucur); 2020; 115(4):448-457. PubMed ID: 32876018
    [No Abstract]   [Full Text] [Related]  

  • 13. Accuracy, Acceptability, and Application: Fecal Immunochemical Tests for Early Detection of Advanced Neoplasia in Colonoscopy-Based Surveillance.
    Wassie MM; Dix M; Laven-Law G; Bulamu N; Cock C; Bampton P; Fraser RJ; Winter JM; Young GP; Symonds EL
    Dig Dis Sci; 2024 Jul; 69(7):2621-2630. PubMed ID: 38753241
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of Colonoscopy Outreach vs Fecal Immunochemical Test Outreach on Colorectal Cancer Screening Completion: A Randomized Clinical Trial.
    Singal AG; Gupta S; Skinner CS; Ahn C; Santini NO; Agrawal D; Mayorga CA; Murphy C; Tiro JA; McCallister K; Sanders JM; Bishop WP; Loewen AC; Halm EA
    JAMA; 2017 Sep; 318(9):806-815. PubMed ID: 28873161
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Personalized colorectal cancer screening: study protocol of a mixed-methods study on the effectiveness of tailored intervals based on prior f-Hb concentration in a fit-based colorectal cancer screening program (PERFECT-FIT).
    Breekveldt ECH; Toes-Zoutendijk E; de Jonge L; Spaander MCW; Dekker E; van Kemenade FJ; van Vuuren AJ; Ramakers CRB; Nagtegaal ID; van Leerdam ME; Lansdorp-Vogelaar I
    BMC Gastroenterol; 2023 Feb; 23(1):45. PubMed ID: 36814185
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Implementation of an organized colorectal cancer screening program through quantitative fecal immunochemical test followed by colonoscopy in an urban low-income community: Guidance and strategies.
    Ribeiro U; Safatle-Ribeiro AV; Sorbello M; Kishi PHR; Cohend DD; Mattar R; Castilho VLP; Goncalves EMDN; Kawaguti F; Marques CFS; Alves VAF; Nahas SC; Eluf-Neto J
    Clinics (Sao Paulo); 2023; 78():100278. PubMed ID: 37639912
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Faecal haemoglobin concentration influences risk prediction of interval cancers resulting from inadequate colonoscopy quality: analysis of the Taiwanese Nationwide Colorectal Cancer Screening Program.
    Chiu SY; Chuang SL; Chen SL; Yen AM; Fann JC; Chang DC; Lee YC; Wu MS; Chou CK; Hsu WF; Chiou ST; Chiu HM
    Gut; 2017 Feb; 66(2):293-300. PubMed ID: 26515543
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Healthcare costs, resource utilization, and productivity loss associated with colorectal cancer screening.
    Engel-Nitz NM; Miller-Wilson LA; Le L; Fisher DA
    Expert Rev Pharmacoecon Outcomes Res; 2023; 23(7):843-852. PubMed ID: 37462667
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Efficacy comparison among high risk factors questionnaire and Asia-Pacific colorectal screening score and their combinations with fecal immunochemical test in screening advanced colorectal tumor].
    Zhu N; Huang YQ; Song YM; Zhang SZ; Zheng S; Yuan Y
    Zhonghua Wei Chang Wai Ke Za Zhi; 2022 Jul; 25(7):612-620. PubMed ID: 35844124
    [No Abstract]   [Full Text] [Related]  

  • 20. Incidence of Interval Colorectal Cancer After Negative Results From First-Round Fecal Immunochemical Screening Tests, by Cutoff Value and Participant Sex and Age.
    Toes-Zoutendijk E; Kooyker AI; Dekker E; Spaander MCW; Opstal-van Winden AWJ; Ramakers C; Buskermolen M; van Vuuren AJ; Kuipers EJ; van Kemenade FJ; Velthuysen MF; Thomeer MGJ; van Veldhuizen H; van Ballegooijen M; Nagtegaal ID; de Koning HJ; van Leerdam ME; Lansdorp-Vogelaar I;
    Clin Gastroenterol Hepatol; 2020 Jun; 18(7):1493-1500. PubMed ID: 31442598
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.